Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence

Overview

Journal Eur Urol Open Sci

Date 2021 Nov 17

PMID 34786563

Citations 6

Authors

Sophie Knipper

Sabine Riethdorf

Stefan Werner

Derya Tilki

Markus Graefen

Klaus Pantel

Tobias Maurer

Affiliations

Soon will be listed here.

Abstract

Patient Summary: We looked at outcomes for lymph node dissection in patients with recurrence of prostate cancer. We found that outcomes appear to be worse when circulating tumour cells (CTCs) can be measured in the blood preoperatively. We conclude that detection of CTCs indicates spread of tumour cells via the blood, which may limit the benefit of lymph node dissection. Thus, CTCs should be investigated in further studies as a potential marker to help in selecting patients who could benefit from lymph node dissection if their prostate cancer recurs.

Citing Articles

Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery.

Mehring G, Steinbach C, Pose R, Knipper S, Koehler D, Werner S World J Urol. 2024; 42(1):256.

PMID: 38656636 PMC: 11043188. DOI: 10.1007/s00345-024-04948-9.

Circulating Tumor Cells: From Basic to Translational Research.

Cortes-Hernandez L, Eslami-S Z, Pantel K, Alix-Panabieres C Clin Chem. 2024; 70(1):81-89.

PMID: 38175586 PMC: 10765989. DOI: 10.1093/clinchem/hvad142.

Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors.

Heidrich I, Deitert B, Werner S, Pantel K Cancer Metastasis Rev. 2023; 42(1):161-182.

PMID: 36607507 PMC: 10014694. DOI: 10.1007/s10555-022-10075-x.

Insights into Circulating Tumor Cell Clusters: A Barometer for Treatment Effects and Prognosis for Prostate Cancer Patients.

Lu L, Hu W, Liu B, Yang T Cancers (Basel). 2022; 14(16).

PMID: 36010983 PMC: 9406494. DOI: 10.3390/cancers14163985.

A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis.

Enikeev D, Morozov A, Babaevskaya D, Bazarkin A, Malavaud B Cancers (Basel). 2022; 14(15).

PMID: 35954464 PMC: 9367494. DOI: 10.3390/cancers14153802.

References

Alix-Panabieres C, Pantel K . Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021; 11(4):858-873. DOI: 10.1158/2159-8290.CD-20-1311. View

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I . Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and.... Eur Urol. 2019; 77(4):403-417. DOI: 10.1016/j.eururo.2019.01.049. View

Rauscher I, Duwel C, Haller B, Rischpler C, Heck M, Gschwend J . Efficacy, Predictive Factors, and Prediction Nomograms for Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol. 2018; 73(5):656-661. DOI: 10.1016/j.eururo.2018.01.006. View

Bravi C, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D . Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol. 2020; 78(5):661-669. PMC: 9084633. DOI: 10.1016/j.eururo.2020.06.043. View

Salami S, Singhal U, Spratt D, Palapattu G, Hollenbeck B, Schonhoft J . Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. JCO Precis Oncol. 2020; 3. PMC: 7440257. DOI: 10.1200/po.18.00352. View

Kirby B, Jodari M, Loftus M, Gakhar G, Pratt E, Chanel-Vos C . Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One. 2012; 7(4):e35976. PMC: 3338784. DOI: 10.1371/journal.pone.0035976. View

Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg N . Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2018; 75(4):659-666. DOI: 10.1016/j.eururo.2018.03.013. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Horn T, Kronke M, Rauscher I, Haller B, Robu S, Wester H . Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery.... Eur Urol. 2019; 76(4):517-523. DOI: 10.1016/j.eururo.2019.03.045. View

10.

Fossati N, Suardi N, Gandaglia G, Bravi C, Soligo M, Karnes R . Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. Eur Urol. 2018; 75(1):176-183. PMC: 9084635. DOI: 10.1016/j.eururo.2018.09.009. View

11.

Pantel K, Hille C, Scher H . Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. Clin Chem. 2019; 65(1):87-99. DOI: 10.1373/clinchem.2018.287102. View